RESUMO
Aims: Decitabine is a drug for the treatment of myelodysplastic syndromes and acute myeloid leukemia. It has a side-effect profile affecting many systems, including dermatologic side effects. Herein, we report a case with a maculopapular-type drug eruption due to decitabine. Presentation of Case: A 51-year-old previously healthy woman was diagnosed with myelodysplastic syndrome RAEB-1, and decitabine [20mg/m2/day/i.v (5 days with cycles repeated every 28 days)] chemotherapy was given. On the seventh day of the second treatment cycle, we diagnosed a maculopapular eruption on the front of the left arm. The patient presented with skin that was itchy, puffy, maculopapular and erythematous. The rash faded when pressed and tended to coalesce with each other, indicating a drug eruption due to decitabine. Maculopapular type drug reaction depending on decitabine was considered. The eruption improved remarkably within 10 days, and the patient's rash had disappeared by the 17th day of treatment. Discussion: Drugs occasionally induce cutaneous side effects. Ecchymosis, rash, erythema, petechiae skin lesion and pruritus have been described in decitabine’s prospectus. Maculopapular eruptions can affect all age groups. This type of eruption is common with certain drugs as well as with several diseases and medical conditions including scarlet fever, measles, rubella, secondary syphilis, parvovirus B19 and heat rash. A number of drugs may cause the appearance of maculopapular eruptions. Conclusion: Practitioners should be aware of this rare, but potentially serious, adverse event, especially as decitabine is commonly used for myelodysplastic syndromes and acute myeloid leukemia.
RESUMO
Aims: Our study was undertaken to examine the laboratory and clinical features of pernicious anemia patients presenting initially at the Turgut Ozal Medical Center, which serves as an important tertiary health center in Eastern Anatolia. Study Design: Among patients evaluated for etiology of anemia, we analysed the clinicopathological characteristics of 300 (158 females and 142 males) patients with pernicious anemia retrospectively. Place and Duration of Study: Department of Internal Medicine and Division of Hematology, Inonu University School of Medicine, between 1996 and July 2011. Methodology: Full blood counts, thyroid hormone levels, liver function tests and LDH levels were reviewed for 300 patients with pernicious anemia retrospectively. Peripheral blood smears and bone marrow biopsies were reviewed by a hematologist. Endoscopic examination and ultrasonographic inspection were performed for atrophic gastritis, gallbladder stones and hepatosplenomegaly for all patients. Laboratory values, ages, signs and symptoms of patients at the time of diagnosis were compared between genders. Results: The mean age of the female patients was 50.56 ± 17.75 years (17–84), while that of the male patients was 57.24 ± 15.78 (20–95) years. At the time of diagnosis, the male patients were older than the females (p = 0.002). LDH levels were significantly higher for females (p = 0.043). The incidence of gallstones was significantly higher in females (25.4%) than in males (10.7%) (p = 0,001). Pancytopenia was defined as a hemoglobin level lower than 10 gr/dl, leukocytes lower than 1.500/μL and platelets lower than 150.000/μL and the incidence of pancytopenia was 41.3% (n = 65) and 50.7% (n = 71) in the female and male patients, respectively, and the difference was not statistically significant. There was no statistically significant difference for frequency of thyroid disease or symptoms and signs at the time of diagnosis between genders. Conclusions: Pernicious anemia is not a disease of only elderly women; it can be seen in both men and women of younger ages. It is seen nearly as often in women as in men. Gallstones and abnormal thyroid activity can be observed at these patients at the time of diagnosis; therefore, these findings should be considered.